NCT04470778View on ClinicalTrials.gov

Study to Assess the Effect of Acid-reducing Agent Famotidine on the Drug Levels of BMS-986256 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

July 20, 2020

Primary Completion Date

March 21, 2021

Study Completion Date

March 28, 2021

Conditions
Healthy Participants
Interventions
DRUG

BMS-986256

Specified dose on specified days

DRUG

Famotidine

Specified dose on specified days

Trial Locations (1)

84124

ICON (LPRA) - Salt Lake, Salt Lake City

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT04470778 - Study to Assess the Effect of Acid-reducing Agent Famotidine on the Drug Levels of BMS-986256 in Healthy Participants | Biotech Hunter | Biotech Hunter